Aşırı Aktif Mesane ve Sıkışma Tipi İnkontinans
Özet
Referanslar
Fontaine C, Papworth E, Pascoe J, et al. Update on the management of overactive bladder. Ther Adv Urol. 2021; Aug; 31;13: 17562872211039034. doi: 10.1177/17562872211039034.
Mancini V, Tarcan T, Serati M, et al. Is coexistent overactive-underactive bladder (with or without detrusor overactivity and underactivity) a real clinical syndrome? ICI-RS 2019. Neurourol Urodyn. 2020; Jul;39 Suppl 3: S50-S59. doi: 10.1002/nau.24311.
Park J, Chang Y, Kim JH, et al. Menopausal stages and overactive bladder symptoms in middle-aged women: A cross-sectional study. BJOG. 2024; Dec;131(13):1805-1814. doi: 10.1111/1471-0528.17912.
Hagovska M, Svihra J Sr, Macko L, et al. The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder. World J Urol. 2024; May 2;42(1):287. doi: 10.1007/s00345-024-04974-7.
Coyne KS, Sexton CC, Kopp ZS, et al. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011; Nov;108(9):1459-71. doi: 10.1111/j.1464-410X.2010.10013.x.
Zhang L, Cai N, Mo L, et al. Global Prevalence of Overactive Bladder: A Systematic Review and Meta-analysis. Int Urogynecol J. 2025; Aug;36(8):1547-1566. doi: 10.1007/s00192-024-06029-2.
Powell LC, Szabo SM, Walker D, et al. The economic burden of overactive bladder in the United States: A systematic literature review. Neurourol Urodyn. 2018; Apr;37(4):1241-1249. doi: 10.1002/nau.23477.
Peyronnet B, Mironska E, Chapple C, et al. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol. 2019; Jun;75(6):988-1000. doi: 10.1016/j.eururo.2019.02.038.
Torosis M, Jackson N, Nitti V, et al. Overactive Bladder Patients With and Without Urgency Incontinence: A Spectrum of One Condition or Different Phenotypes? Urogynecology (Phila). 2023; Jan 1;29(1):33-40. doi: 10.1097/SPV.0000000000001254.
AlQuaiz AM, Kazi A, AlYousefi N, et al. Urinary Incontinence Affects the Quality of Life and Increases Psychological Distress and Low Self-Esteem. Healthcare (Basel). 2023; Jun 15;11(12):1772. doi: 10.3390/healthcare11121772.
Yalazı RÖ, Demirci N. The effect of bladder training with mobile application on quality of life and sexual satisfaction in women with overactive bladder: randomized controlled study. World J Urol. 2025; Sep 25;43(1):573. doi: 10.1007/s00345-025-05917-6.
Yang CF, Huang CY, Wang SY, et al. Prevalence of and Associated Factors for Overactive Bladder Subtypes in Middle-Aged Women: A Cross-Sectional Study. Medicina (Kaunas). 2022; Mar 4;58(3):383. doi: 10.3390/medicina58030383.
Park J, Chang Y, Kim JH, et al. Menopausal stages and overactive bladder symptoms in middle-aged women: A cross-sectional study. BJOG. 2024; Dec;131(13):1805-1814. doi: 10.1111/1471-0528.17912.
Shapiro KK, Brucker BM. Treatment of overactive bladder in men: Is it really different? Neurourol Urodyn. 2022; Nov;41(8):1975-1982. doi: 10.1002/nau.25000.
Cheng Y, Chen T, Zheng G, et al. Prevalence and trends in overactive bladder among men in the United States, 2005-2020. Sci Rep. 2024; Jul 15;14(1):16284. doi: 10.1038/s41598-024-66758-8.
Lin W, Li T, Xu Z, et al. Association of socioeconomic status and overactive bladder in US adults: a cross-sectional analysis of nationally representative data. Front Public Health. 2024; Mar 26;12:1345866. doi: 10.3389/fpubh.2024.1345866.
Duperrouzel C, Martin C, Mendell A, et al. Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review. J Comp Eff Res. 2022; Dec;11(18):1375-1394. doi: 10.2217/cer-2022-0160.
Hanna-Mitchell AT, Kashyap M, Chan WV, et al. Pathophysiology of idiopathic overactive bladder and the success of treatment: a systematic review from ICI-RS 2013. Neurourol Urodyn. 2014; Jun;33(5):611-7. doi: 10.1002/nau.22582.
Chapple C. Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "overactive bladder". Neurourol Urodyn. 2014; Jul;33 Suppl 3:S6-13. doi: 10.1002/nau.22635.
Varelas E, Antoniadis G, Tsionga A, et al. Association between prostatic inflammation and detrusor overactivity in men with benign prostatic hyperplasia and bladder outlet obstruction: a prospective urodynamic and histological study. Prostate Cancer Prostatic Dis. 2025; Oct 29. doi: 10.1038/s41391-025-01039-7.
Frigerio M, Barba M, Cola A, et al. Coexisting overactive-underactive bladder and detrusor overactivity-underactivity in pelvic organ prolapse. Int J Gynaecol Obstet. 2023; Jan;160(1):256-262. doi: 10.1002/ijgo.14288.
Fernández-Alonso AM, López-Baena MT, García-Alfaro P, et al. Systematic review and meta-analysis on the association of metabolic syndrome in women with overactive bladder. Gynecol Endocrinol. 2025; Dec;41(1):2445682. doi: 10.1080/09513590.2024.2445682.
Li T, Hou J, Xiao B, et al. Combined healthy lifestyles and overactive bladder: a cross-sectional study of NHANES 2007-2020. Front Nutr. 2025; Jul 1;12:1603078. doi: 10.3389/fnut.2025.1603078.
Krhut J, Kobberø H, Kanaan R, et al. The mechanism of action of neuromodulation in the treatment of overactive bladder. Nat Rev Urol. 2025; Jul;22(7):414-426. doi: 10.1038/s41585-024-00967-8.
Grundy L, Wyndaele JJ, Hashitani H, et al. How does the lower urinary tract contribute to bladder sensation? ICI-RS 2023. Neurourol Urodyn. 2024; Aug;43(6):1293-1302. doi: 10.1002/nau.25316.
Fernández-Alonso AM, López-Baena MT, García-Alfaro P, et al. Systematic review and meta-analysis on the association of metabolic syndrome in women with overactive bladder. Gynecol Endocrinol. 2025; Dec;41(1):2445682. doi: 10.1080/09513590.2024.2445682.
Khadour FA, Khadour YA, Alhatem W, et al. Risk factors associated with overactive bladder severity in patients with type 2 diabetes. Neurourol Urodyn. 2024; Nov;43(8):1835-1841. doi: 10.1002/nau.25567.
Nitti VW, Patel A, Karram M. Diagnosis and management of overactive bladder: A review. J Obstet Gynaecol Res. 2021; May;47(5):1654-1665. doi: 10.1111/jog.14708.
Kontogiannis S, Athanasopoulos A, Tsagkarakis M, et al. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder. Int Urogynecol J. 2022; Nov;33(11):3035-3043. doi: 10.1007/s00192-021-04991-9.
Dobberfuhl AD. Pathophysiology, assessment, and treatment of overactive bladder symptoms in patients with interstitial cystitis/bladder pain syndrome. Neurourol Urodyn. 2022; Nov;41(8):1958-1966. doi: 10.1002/nau.24958.
Abdel-Fattah M, Chapple C, Cooper D, et al. Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trial. Lancet. 2025; Mar 29;405(10484):1057-1068. doi: 10.1016/S0140-6736(24)01886-5.
Walter M, Leitner L, Betschart C, et al. Considering non-bladder aetiologies of overactive bladder: a functional neuroimaging study. BJU Int. 2021; Nov;128(5):586-597. doi: 10.1111/bju.15354.
Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. J Urol. 2024; Jul;212(1):11-20. doi: 10.1097/JU.0000000000003985.
Funada S, Luo Y, Uozumi R, et al. Multicomponent Intervention for Overactive Bladder in Women: A Randomized Clinical Trial. JAMA Netw Open. 2024; Mar 4;7(3):e241784. doi: 10.1001/jamanetworkopen.2024.1784.
Funada S, Yoshioka T, Luo Y, et al. Bladder training for treating overactive bladder in adults. Cochrane Database Syst Rev. 2023; Oct 9;10(10):CD013571. doi: 10.1002/14651858.CD013571.pub2.
Mohamud H, Sinclair S, Gunamany S, et al. Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns. Neurourol Urodyn. 2025; Feb;44(2):319-329. doi: 10.1002/nau.25627.
Kachru N, Holmes HM, Johnson ML, et al. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Curr Med Res Opin. 2021; Aug;37(8):1303-1313. doi: 10.1080/03007995.2021.1920899.
He W, Zhang Y, Huang G, et al. Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. Low Urin Tract Symptoms. 2023; May;15(3):80-88. doi: 10.1111/luts.12475.
Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015; Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012.
Nitti VW, Ginsberg D, Sievert KD, et al. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol. 2016; Sep;196(3):791-800. doi: 10.1016/j.juro.2016.03.146.
Tilborghs S, De Wachter S. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects. Expert Rev Med Devices. 2022; Feb;19(2):161-187. doi: 10.1080/17434440.2022.2032655.
McPhail C, Carey R, Nambiar S, et al. The Investigation of Percutaneous Tibial Nerve Stimulation (PTNS) as a Minimally Invasive, Non-Surgical, Non-Hormonal Treatment for Overactive Bladder Symptoms. J Clin Med. 2023; May 16;12(10):3490. doi: 10.3390/jcm12103490.
Sweeney T, Zilinskas K, Cox L. Botulinumtoxin Injection Versus Augmentation Cystoplasty for Neurogenic Bladder: Where Do We Stand?. Curr Bladder Dysfunct Rep. 2023;18;299–303 doi.org/10.1007/s11884-023-00719-1.
Gibson S, Ellsworth P. Emerging therapies for overactive bladder: preclinical, phase I and phase II studies. Expert Opin Investig Drugs. 2024; Jun;33(6):601-612. doi: 10.1080/13543784.2024.2349285.
Krhut J, Skugarevská B, Míka D, et al. Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations. Res Rep Urol. 2022; Apr 26;14:167-175. doi: 10.2147/RRU.S309144.
Brady CM, Apostolidis A, Yiangou Y, et al. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol. 2004; Aug;46(2):247-53. doi: 10.1016/j.eururo.2003.12.017.
Başaranoğlu M, Taşdemir İK, Akbay E, et al. Artificial intelligence-based prediction of treatment failure and medication non-adherence in overactive bladder management. BMC Urol. 2025; Aug 21;25(1):209. doi: 10.1186/s12894-025-01911-7.
Referanslar
Fontaine C, Papworth E, Pascoe J, et al. Update on the management of overactive bladder. Ther Adv Urol. 2021; Aug; 31;13: 17562872211039034. doi: 10.1177/17562872211039034.
Mancini V, Tarcan T, Serati M, et al. Is coexistent overactive-underactive bladder (with or without detrusor overactivity and underactivity) a real clinical syndrome? ICI-RS 2019. Neurourol Urodyn. 2020; Jul;39 Suppl 3: S50-S59. doi: 10.1002/nau.24311.
Park J, Chang Y, Kim JH, et al. Menopausal stages and overactive bladder symptoms in middle-aged women: A cross-sectional study. BJOG. 2024; Dec;131(13):1805-1814. doi: 10.1111/1471-0528.17912.
Hagovska M, Svihra J Sr, Macko L, et al. The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder. World J Urol. 2024; May 2;42(1):287. doi: 10.1007/s00345-024-04974-7.
Coyne KS, Sexton CC, Kopp ZS, et al. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011; Nov;108(9):1459-71. doi: 10.1111/j.1464-410X.2010.10013.x.
Zhang L, Cai N, Mo L, et al. Global Prevalence of Overactive Bladder: A Systematic Review and Meta-analysis. Int Urogynecol J. 2025; Aug;36(8):1547-1566. doi: 10.1007/s00192-024-06029-2.
Powell LC, Szabo SM, Walker D, et al. The economic burden of overactive bladder in the United States: A systematic literature review. Neurourol Urodyn. 2018; Apr;37(4):1241-1249. doi: 10.1002/nau.23477.
Peyronnet B, Mironska E, Chapple C, et al. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol. 2019; Jun;75(6):988-1000. doi: 10.1016/j.eururo.2019.02.038.
Torosis M, Jackson N, Nitti V, et al. Overactive Bladder Patients With and Without Urgency Incontinence: A Spectrum of One Condition or Different Phenotypes? Urogynecology (Phila). 2023; Jan 1;29(1):33-40. doi: 10.1097/SPV.0000000000001254.
AlQuaiz AM, Kazi A, AlYousefi N, et al. Urinary Incontinence Affects the Quality of Life and Increases Psychological Distress and Low Self-Esteem. Healthcare (Basel). 2023; Jun 15;11(12):1772. doi: 10.3390/healthcare11121772.
Yalazı RÖ, Demirci N. The effect of bladder training with mobile application on quality of life and sexual satisfaction in women with overactive bladder: randomized controlled study. World J Urol. 2025; Sep 25;43(1):573. doi: 10.1007/s00345-025-05917-6.
Yang CF, Huang CY, Wang SY, et al. Prevalence of and Associated Factors for Overactive Bladder Subtypes in Middle-Aged Women: A Cross-Sectional Study. Medicina (Kaunas). 2022; Mar 4;58(3):383. doi: 10.3390/medicina58030383.
Park J, Chang Y, Kim JH, et al. Menopausal stages and overactive bladder symptoms in middle-aged women: A cross-sectional study. BJOG. 2024; Dec;131(13):1805-1814. doi: 10.1111/1471-0528.17912.
Shapiro KK, Brucker BM. Treatment of overactive bladder in men: Is it really different? Neurourol Urodyn. 2022; Nov;41(8):1975-1982. doi: 10.1002/nau.25000.
Cheng Y, Chen T, Zheng G, et al. Prevalence and trends in overactive bladder among men in the United States, 2005-2020. Sci Rep. 2024; Jul 15;14(1):16284. doi: 10.1038/s41598-024-66758-8.
Lin W, Li T, Xu Z, et al. Association of socioeconomic status and overactive bladder in US adults: a cross-sectional analysis of nationally representative data. Front Public Health. 2024; Mar 26;12:1345866. doi: 10.3389/fpubh.2024.1345866.
Duperrouzel C, Martin C, Mendell A, et al. Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review. J Comp Eff Res. 2022; Dec;11(18):1375-1394. doi: 10.2217/cer-2022-0160.
Hanna-Mitchell AT, Kashyap M, Chan WV, et al. Pathophysiology of idiopathic overactive bladder and the success of treatment: a systematic review from ICI-RS 2013. Neurourol Urodyn. 2014; Jun;33(5):611-7. doi: 10.1002/nau.22582.
Chapple C. Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "overactive bladder". Neurourol Urodyn. 2014; Jul;33 Suppl 3:S6-13. doi: 10.1002/nau.22635.
Varelas E, Antoniadis G, Tsionga A, et al. Association between prostatic inflammation and detrusor overactivity in men with benign prostatic hyperplasia and bladder outlet obstruction: a prospective urodynamic and histological study. Prostate Cancer Prostatic Dis. 2025; Oct 29. doi: 10.1038/s41391-025-01039-7.
Frigerio M, Barba M, Cola A, et al. Coexisting overactive-underactive bladder and detrusor overactivity-underactivity in pelvic organ prolapse. Int J Gynaecol Obstet. 2023; Jan;160(1):256-262. doi: 10.1002/ijgo.14288.
Fernández-Alonso AM, López-Baena MT, García-Alfaro P, et al. Systematic review and meta-analysis on the association of metabolic syndrome in women with overactive bladder. Gynecol Endocrinol. 2025; Dec;41(1):2445682. doi: 10.1080/09513590.2024.2445682.
Li T, Hou J, Xiao B, et al. Combined healthy lifestyles and overactive bladder: a cross-sectional study of NHANES 2007-2020. Front Nutr. 2025; Jul 1;12:1603078. doi: 10.3389/fnut.2025.1603078.
Krhut J, Kobberø H, Kanaan R, et al. The mechanism of action of neuromodulation in the treatment of overactive bladder. Nat Rev Urol. 2025; Jul;22(7):414-426. doi: 10.1038/s41585-024-00967-8.
Grundy L, Wyndaele JJ, Hashitani H, et al. How does the lower urinary tract contribute to bladder sensation? ICI-RS 2023. Neurourol Urodyn. 2024; Aug;43(6):1293-1302. doi: 10.1002/nau.25316.
Fernández-Alonso AM, López-Baena MT, García-Alfaro P, et al. Systematic review and meta-analysis on the association of metabolic syndrome in women with overactive bladder. Gynecol Endocrinol. 2025; Dec;41(1):2445682. doi: 10.1080/09513590.2024.2445682.
Khadour FA, Khadour YA, Alhatem W, et al. Risk factors associated with overactive bladder severity in patients with type 2 diabetes. Neurourol Urodyn. 2024; Nov;43(8):1835-1841. doi: 10.1002/nau.25567.
Nitti VW, Patel A, Karram M. Diagnosis and management of overactive bladder: A review. J Obstet Gynaecol Res. 2021; May;47(5):1654-1665. doi: 10.1111/jog.14708.
Kontogiannis S, Athanasopoulos A, Tsagkarakis M, et al. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder. Int Urogynecol J. 2022; Nov;33(11):3035-3043. doi: 10.1007/s00192-021-04991-9.
Dobberfuhl AD. Pathophysiology, assessment, and treatment of overactive bladder symptoms in patients with interstitial cystitis/bladder pain syndrome. Neurourol Urodyn. 2022; Nov;41(8):1958-1966. doi: 10.1002/nau.24958.
Abdel-Fattah M, Chapple C, Cooper D, et al. Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trial. Lancet. 2025; Mar 29;405(10484):1057-1068. doi: 10.1016/S0140-6736(24)01886-5.
Walter M, Leitner L, Betschart C, et al. Considering non-bladder aetiologies of overactive bladder: a functional neuroimaging study. BJU Int. 2021; Nov;128(5):586-597. doi: 10.1111/bju.15354.
Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. J Urol. 2024; Jul;212(1):11-20. doi: 10.1097/JU.0000000000003985.
Funada S, Luo Y, Uozumi R, et al. Multicomponent Intervention for Overactive Bladder in Women: A Randomized Clinical Trial. JAMA Netw Open. 2024; Mar 4;7(3):e241784. doi: 10.1001/jamanetworkopen.2024.1784.
Funada S, Yoshioka T, Luo Y, et al. Bladder training for treating overactive bladder in adults. Cochrane Database Syst Rev. 2023; Oct 9;10(10):CD013571. doi: 10.1002/14651858.CD013571.pub2.
Mohamud H, Sinclair S, Gunamany S, et al. Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns. Neurourol Urodyn. 2025; Feb;44(2):319-329. doi: 10.1002/nau.25627.
Kachru N, Holmes HM, Johnson ML, et al. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Curr Med Res Opin. 2021; Aug;37(8):1303-1313. doi: 10.1080/03007995.2021.1920899.
He W, Zhang Y, Huang G, et al. Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. Low Urin Tract Symptoms. 2023; May;15(3):80-88. doi: 10.1111/luts.12475.
Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015; Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012.
Nitti VW, Ginsberg D, Sievert KD, et al. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol. 2016; Sep;196(3):791-800. doi: 10.1016/j.juro.2016.03.146.
Tilborghs S, De Wachter S. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects. Expert Rev Med Devices. 2022; Feb;19(2):161-187. doi: 10.1080/17434440.2022.2032655.
McPhail C, Carey R, Nambiar S, et al. The Investigation of Percutaneous Tibial Nerve Stimulation (PTNS) as a Minimally Invasive, Non-Surgical, Non-Hormonal Treatment for Overactive Bladder Symptoms. J Clin Med. 2023; May 16;12(10):3490. doi: 10.3390/jcm12103490.
Sweeney T, Zilinskas K, Cox L. Botulinumtoxin Injection Versus Augmentation Cystoplasty for Neurogenic Bladder: Where Do We Stand?. Curr Bladder Dysfunct Rep. 2023;18;299–303 doi.org/10.1007/s11884-023-00719-1.
Gibson S, Ellsworth P. Emerging therapies for overactive bladder: preclinical, phase I and phase II studies. Expert Opin Investig Drugs. 2024; Jun;33(6):601-612. doi: 10.1080/13543784.2024.2349285.
Krhut J, Skugarevská B, Míka D, et al. Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations. Res Rep Urol. 2022; Apr 26;14:167-175. doi: 10.2147/RRU.S309144.
Brady CM, Apostolidis A, Yiangou Y, et al. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol. 2004; Aug;46(2):247-53. doi: 10.1016/j.eururo.2003.12.017.
Başaranoğlu M, Taşdemir İK, Akbay E, et al. Artificial intelligence-based prediction of treatment failure and medication non-adherence in overactive bladder management. BMC Urol. 2025; Aug 21;25(1):209. doi: 10.1186/s12894-025-01911-7.
